Population screening with prostate-specific antigen is not recommended as the benefits have not been shown to clearly outweigh the harms.

• Patients who are specifically concerned about prostate cancer can make the informed decision to undergo screening with PSA. Clinicians should not test for asymptomatic prostate cancer without counselling about the possible harms, as well as the possible benefits.
• PSA can be elevated in a number of situations, including prostate cancer, after prostate biopsy or TURP, in prostatitis, urinary retention or with recent ejaculation.

[https://www.racgp.org.au/FSDEDEV/media/documents/Patient information/prostate-cancer-screening-infosheet.pdf](https://www.racgp.org.au/FSDEDEV/media/documents/Patient information/prostate-cancer-screening-infosheet.pdf)